NTT-DATA
18.7.2024 14:01:34 CEST | Business Wire | Press release
NTT DATA, a leading IT infrastructure and services company, unveiled its new Edge AI platform to accelerate IT/OT convergence by bringing AI processing to the edge. By processing data when and where it is generated and unifying diverse IoT devices, systems and data, this unique, fully managed solution enables real-time decisions, enhanced operational efficiencies and secure AI application deployment across industries to drive advanced Industry 4.0 technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240718015818/en/
NTT DATA unveiled a new ultralight Edge AI platform, a fully managed service that allows enterprises to deploy AI applications at the edge using smaller, more efficient language learning models that deliver immediate AI insights. [Source: NTT DATA]
While the spotlight has been on GenAI and Large Language Models (LLMs), these technologies are impractical for industries requiring real-time and local decision-making. NTT DATA’s Edge AI solution addresses this challenge by processing massive data sets on compact computing platforms, using smaller, more efficient machine learning models to deliver real-time AI insights.
NTT DATA’s Edge AI is an all-inclusive managed service platform that includes all the systems, tools and capabilities required for AI at the edge. It addresses data discovery, collection, integration, computation power, seamless connectivity and AI model management.
The Edge AI platform, supported by NTT DATA’s consulting data scientists, managed services and global technical resources, addresses the shadow IoT challenge and AI infrastructure requirements. It does this by auto-discovering, unifying and processing data from IoT devices and IT assets across the organization, simplifying AI deployment and management.
Solving industry-specific challenges with AI-driven insights
Designed to support industry-specific requirements, the Edge AI platform leverages lighter, cost-effective AI models, enabling it to run within a small compute box. Edge AI will perform specific tasks, such as supporting safety or operational efficiency, by collecting data from disparate devices across a network environment, enabling instantaneous and secure data processing and analytics.
Manufacturing operations could benefit from improved predictive maintenance by accessing IT/OT data from sensors, machinery, cameras and applications to plan and address failures. In addition, NTT DATA’s Edge AI can monitor and optimize energy consumption in real time, predicting energy spikes and optimizing machine usage, reducing costs and CO2 emissions with renewable energy.
“Our Edge AI platform represents a significant leap forward in driving AI at the edge securely and cost-effectively,” said Shahid Ahmed, Group Executive Vice President of Edge Services at NTT DATA. “By harmonizing data from disparate sensors and devices with lightweight AI models, powering all kinds of automation use-cases, NTT DATA’s Edge AI is pioneering industrial AI adoption as the first fully managed offering, helping organizations modernize with tailored, industry-specific solutions.”
Seizing the US$200 billion market opportunity
According to IDC, worldwide spending on edge computing is expected to reach US$232 billion in 2024, an increase of 15% over 2023. This growth is perpetuated by the growing number of connected IoT devices worldwide, expected to exceed 41 billion by 2025.
NTT DATA is poised to capture significant market share through its dedicated IoT consulting and services business, which brings together 1,000 industry experts, hundreds of use cases from predictive maintenance, fleet management, connected factories, energy consumption monitoring and sustainability, and has already trained over 500 sales experts globally to accelerate its Edge AI go-to-market efforts.
NTT DATA’s Edge AI deployment approach allows clients to take advantage of a free 30-day discovery and diagnostic of their IT and OT environment. The software auto-discovers assets with its vast library of pre-built OT interfaces. After this initial stage, Edge AI software generates a comprehensive diagnostic report inventorying assets and data streams, including identifying security risks and vulnerabilities.
“A key challenge for enterprises is reliably capturing and aggregating operational data securely across a fragmented landscape of devices, platforms and data sources and turning it into actionable insights,” said Alejandro Cadenas, Associate Vice President, Telco Mobility & IoT Research, IDC Europe. “NTT DATA’s ultralight Edge AI addresses these issues and simplifies the deployment and adoption of a data-driven enterprise strategy, reducing risks and timelines and optimizing total cost of ownership and value for the enterprise."
Driving secure AI adoption at the edge with the first fully managed service
NTT DATA’s managed services for Edge AI offer a unified view and management of devices, sensors and assets. With expert support and advanced technologies, NTT DATA helps businesses simplify complex processes, drive cost savings, enhance performance and accelerate digital transformation.
As the industry’s first fully managed IT/OT convergence platform, Edge AI transforms physical assets into software assets for data-driven insights, regardless of the manufacturer. Operating at the edge, managed services integrate OT assets with IT applications, boosting operational efficiency. Edge AI also provides a view of the firmware version of all connected devices to promote vulnerability patching and overall device security.
“Computing and AI must happen where they create the most value for the enterprise; for many industrial enterprises this is where the data is generated. By ingesting IT and OT data and leveraging AI models to drive use-case specific results, the NTT DATA solution takes another step towards realizing the industry 4.0 vision,” said Pablo Tomasi, Principal Analyst, Private Network, Omdia. “Additionally, using task-specific small AI models will help drive AI democratization by making it is easier for the enterprise to introduce AI where and when is needed, without the need for an extensive overhaul of their whole infrastructure.”
Edge AI rounds out NTT DATA’s comprehensive Edge portfolio, which includes Enterprise IoT, Edge Compute, Private 5G and Device as a Service.
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. We invest over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group and headquartered in Tokyo. Visit us at nttdata.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718015818/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
